Ignite Creation Date:
2025-12-25 @ 4:30 AM
Ignite Modification Date:
2025-12-26 @ 3:33 AM
Study NCT ID:
NCT03524118
Status:
COMPLETED
Last Update Posted:
2025-01-14
First Post:
2018-05-11
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-09-20
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-09-14
Completion Date Type:
ACTUAL
First Submit Date:
2018-05-11
First Submit QC Date:
None
Study First Post Date:
2018-05-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-08-29
Results First Submit QC Date:
None
Results First Post Date:
2023-11-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-06
Last Update Post Date:
2025-01-14
Last Update Post Date Type:
ACTUAL